Dr. Lisa A. Jackson ’84 has conducted numerous vaccine studies, but the task before her in March was different — the timing compressed, the stakes higher — when her team launched one of the first human clinical trials for a vaccine to block infection from the virus that causes COVID-19. In the face of a global pandemic, this vaccine represented hope.
As Dr. Jennifer Primeggia '02 and her partners in the infectious diseases group at a Washington, D.C.-area hospital fight to save lives, COVID-19 is putting a strain on supplies and health care workers.
The idea of buying a home for retirement near William & Mary seems to be gaining momentum among alumni who value the opportunity to return to a familiar setting filled with treasured memories; to enjoy the cultural, recreational and intellectual benefits of living close to a university; and to strengthen bonds with others in the W&M community.
How do you have fun, meet people and form meaningful relationships while wearing masks, gathering in small numbers and maintaining a 6-foot distance from others? Thanks to the perseverance and creativity of university staff and student organizations, there are numerous ways to answer that question.
Studio for Teaching & Learning Innovation addresses evolving classroom needs
By Tina Eshleman
Relying on medical research, scientific data, guidance from federal and state agencies, and consultation with professional peers, William & Mary's six-member Public Health Advisory Team weighs health concerns and practical effects of the university’s pandemic response on the lives of students, faculty and staff.
Maj. George M. “Chip” Autry V ’02 and Maj. Lance Barlowe ’06 are part of the team of military service members and civilians responsible for planning and implementing delivery of 300 million vaccine doses throughout the United States and its territories in the fight against COVID-19.
As the chief scientific officer of platform research at Massachusetts-based Moderna Inc., Melissa J. Moore ’84 is a key part of the biotech company’s effort to produce 200 million COVID-19 vaccines for the U.S. government to distribute to Americans across the country.